株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

癌治療におけるゲノミクス市場分析:製品別 (装置、消耗品、サービス) 、用途別 (診断、個別化医療、創薬・開発、研究) 、技術別、エンドユース別、および2022年までのセグメント予測

Genomics In Cancer Care Market Analysis By Product (Instruments, Consumables, Services), By Application (Diagnostics, Personalized Medicine, Drug Discovery & Development, Research), By Technology, By End-use And Segment Forecasts To 2022

発行 Grand View Research, Inc. 商品コード 355225
出版日 ページ情報 英文 80 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=110.35円で換算しております。
Back to Top
癌治療におけるゲノミクス市場分析:製品別 (装置、消耗品、サービス) 、用途別 (診断、個別化医療、創薬・開発、研究) 、技術別、エンドユース別、および2022年までのセグメント予測 Genomics In Cancer Care Market Analysis By Product (Instruments, Consumables, Services), By Application (Diagnostics, Personalized Medicine, Drug Discovery & Development, Research), By Technology, By End-use And Segment Forecasts To 2022
出版日: 2016年02月07日 ページ情報: 英文 80 Pages
概要

世界の癌治療におけるゲノミクス市場は、2022年までに92億2,000万米ドルに達すると予測されています。癌の罹患率上昇と診断、治療のための次世代シーケンシングの導入により、市場の将来的成長の機会を加速させるとみられています。また今後、費用対効果の高い正確な診断薬の需要も高まると予測されています。

当レポートでは、世界の癌治療におけるゲノミクス市場の現状と2022年までの成長見通し、製品別、用途別、技術別、エンドユース別動向、および主要企業のプロファイルなどをまとめています。

第1章 調査方法と調査範囲

第2章 エグゼクティブサマリー

第3章 業界見通し

  • 市場セグメンテーション
  • 市場規模と成長見通し
  • 市場動向
    • 促進因子
    • 阻害因子
  • 市場の機会
  • 業界分析:ポーターズ
  • PESTEL分析

第4章 製品別市場見通し

  • 製品別収益シェア
  • 装置
  • 消耗品および試薬
  • サービス

第5章 用途別見通し

  • 用途別収益シェア
  • 診断
  • 個別化医療
  • 創薬・開発
  • 研究

第6章 技術別市場見通し

  • 技術別収益シェア
  • ゲノムシーケンシング
  • ポリメラーゼ連鎖反応 (PCR)
  • マイクロアレイ
  • 核酸抽出および精製
  • その他 (フローサイトメトリー、バイオインフォマティクス)

第7章 エンドユース別見通し

  • エンドユース別収益シェア
  • 病院
  • 研究機関
  • 学術機関
  • その他

第8章 地域別見通し

  • 地域別市場シェア
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 競合環境

  • Illumina Inc
  • Agilent Technologies
  • Roche Diagnostics
  • Cancer Genetics Inc
  • Bio-Rad Laboratories
  • Sigma Aldrich
  • Qiagen
  • Perkin Elmer
  • Affymetrix
  • BGI
  • Life technologies
  • GE Healthcare
  • Pacific Biosciences
  • Quest Diagnostics
  • Myriad Genetics
  • Luminex
  • Abbott Molecular
  • Beckman Coulter, Inc
  • Oxford Gene Technology Ltd.

図表

目次
Product Code: 978-1-68038-717-9

Global genomics in cancer care market is expected to reach USD 9.22 billion by 2022, according to a new report by Grand View Research, Inc. Increasing prevalence of cancer coupled with adoption of next generation sequencing for the diagnosis & treatment is expected to fuel the market with future growth opportunities. Increasing incidences of cancer triggers the demand for cost effective and accurate diagnostics in coming years.

In addition, increasing demand for personalized medicines in molecular characterization of cancer to identify therapeutic targets is the factor attributing towards the market growth. Similarly, factors such as cost reduction in genome sequencing, growing healthcare expenditure levels and development of effective diagnostics & therapeutic procedures for cancer are responsible for the potential growth of genomics in cancer care.

Further key findings from the study suggest:

Instrument segment dominated the overall market in terms of revenue share as of 2014 and accounted for 33.4% of market owing to high cost associated with it. Whereas, consumables are most widely used product segment in genome testing as they are indispensible component and frequently required to perform the test.

Demand for services such as next generation sequencing, PCR and other such as cancer risk management & genetic testing are expected to grow over the forecast period due to increasing outsourcing activities to perform genome analysis. High cost of performing genetic tests and growing awareness pertaining to associated benefits with the use of these technologies are high impact rendering drivers for this segment.

Drug discovery and development segment is expected to show lucrative CAGR of 17.6% during the forecast period owing to increasing demand for effective treatment for cancer and growing investment in biomedicines by manufacturers for the development of novel products.

Genome sequencing held the dominant share of technology segment as it is most prominently used for diagnosis due to associate benefits such as faster and accurate method. It is expected to show significant growth rate of 17.5% in coming years owing to remarkable decrease in the cost for genome sequencing and increasing adoption rates.

The cancer research segment held the largest share of 34.1% in 2014 due to increasing demand for faster & accurate diagnostic methods to treat variety of cancer. Other use such as commercial adoption of genetic testing is expected to be fastest growing segment owing to increasing demand of cancer genomic testing to fulfill unmet needs in healthcare sector.

Some key players operating in this market include Beckman Coulter Inc., Illumina, Inc, Affymetrix, Roche Diagnostics, Agilent Technologies, Cancer Genetics Inc., Danaher Corporation, Bio-Rad Labs, Pacific Biosciences, Quest Diagnostics, Sigma Aldrich, Luminex, Thermo Fisher scientific, Oxford Gene Technology., PerkinElmer, Qiagen, and GE Healthcare.

Table of Content

Chapter 1. Methodology and Scope

  • 1.1. Research methodology
  • 1.2. Research scope & assumptions
  • 1.3. List of data sources

Chapter 2. Executive Summary

  • 2.1. Genomics in cancer care- Industry Snapshot And Key Buying Criteria, 2012-2022

Chapter 3. Genomics In Cancer Care Industry Outlook

  • 3.1. Genomics in cancer care market segmentation
  • 3.2. Genomics in cancer care market size and growth prospects
  • 3.3. Genomics in cancer care market dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Key opportunities prioritized
  • 3.5. Industry Analysis - Porter's
  • 3.6. Genomics in cancer care market PESTEL analysis, 2014

Chapter 4. Genomics In Cancer Care Product Outlook

  • 4.1. Genomics in cancer care market share by product, 2014 & 2022
  • 4.2. Instruments
    • 4.2.1. Instruments market, 2012-2020 (USD Million)
  • 4.3. Consumables & reagents
    • 4.3.1. Consumables & reagents market, 2012 - 2020 (USD Million)
  • 4.4. Services
    • 4.4.1. Services market estimates and forecasts, 2012 f 2022 (USD Million)

Chapter 5. Genomics In Cancer Care Application Outlook

  • 5.1. Genomics in cancer care revenue share by application, 2013 & 2020
  • 5.2. Diagnostics
    • 5.2.1. Market estimates and forecasts, 2012 - 2020 (USD Million)
  • 5.3. Personalized medicine
    • 5.3.1. Market estimates and forecasts, 2012 - 2020 (USD Million)
  • 5.4. Drug discovery & development
      • 5.4.1.Market estimates and forecasts, 2012 - 2020 (USD Million)
  • 5.5. Research
    • 5.5.1. Market estimates and forecasts, 2012 - 2020 (USD Million))

Chapter 6. Genomics In Cancer Care Technology Outlook

  • 6.1. Genomics in cancer care revenue share by technology, 2013& 2020
  • 6.2. Genome sequencing
    • 6.2.1. Genome sequencing market estimates and forecasts, 2012 - 2020 (USD Million)
  • 6.3. Polymerase chain reaction (PCR)
    • 6.3.1. PCR market estimates and forecasts, 2012 - 2020 (USD Million)
  • 6.4. Microarray
    • 6.4.1. Microarray market estimates and forecasts, 2012 - 2020 (USD Million)
  • 6.5. Nucleic acid extraction and purification
    • 6.5.1. Nucleic acid extraction and purification market estimates and forecasts, 2012 - 2020 (USD Million)
  • 6.6. Other (Flow cytometry, Bioinformatics)
    • 6.6.1. Other market estimates and forecasts, 2012 - 2020 (USD Million)

Chapter 7. Genomics In Cancer Care End-use Outlook

  • 7.1. Genomics in cancer care revenue share by end-use, 2013& 2020
  • 7.2. Hospitals
    • 7.2.1. Hospitals market estimates and forecasts, 2012 - 2020 (USD Million)
  • 7.3. Research institutes
    • 7.3.1. Research institutes market estimates and forecasts, 2012 - 2020 (USD Million)
  • 7.4. Academic institutes
    • 7.4.1. Academic institutes market estimates and forecasts, 2012 - 2020 (USD Million)
  • 7.5. Others (diagnostic labs, commercial organizations & physician office)
    • 7.5.1. Other market estimates and forecasts, 2012 - 2020 (USD Million)

Chapter 8. Genomics In Cancer Care Regional Outlook

  • 8.1. Genomics in cancer care market share by region, 2014 & 2022
  • 8.2. North America
    • 8.2.1. North America Market Estimates and Forecasts, by Application, 2012 - 2022 (USD Million)
      • 8.2.1.1. U.S. Market Estimates and Forecasts
      • 8.2.1.2. Canada Market Estimates and Forecasts
  • 8.3. Europe
    • 8.3.1. Europe Market Estimates and Forecasts, by Application, 2012 - 2022 (USD Million)
      • 8.3.1.1. Germany Market Estimates and Forecasts
      • 8.3.1.2. UK Market Estimates and Forecasts
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Market Estimates and Forecasts, by Division, 2012 - 2022 (USD Million)
      • 8.4.1.1. Japan Market Estimates and Forecasts
      • 8.4.1.2. China Market Estimates and Forecasts
      • 8.4.1.3. India Market Estimates and Forecasts
  • 8.5. Latin America
    • 8.5.1. Latin America Market Estimates and Forecasts, by Division, 2012 - 2022 (USD Million)
      • 8.5.1.1. Brazil Market Estimates and Forecasts
      • 8.5.1.2. Mexico Market Estimates and Forecasts
  • 8.6. MEA
    • 8.6.1. MEA Market Estimates and Forecasts, by Division, 2012 - 2022 (USD Million)
      • 8.6.1.1. South Africa Estimates and Forecasts

Chapter 9. Competitive Landscape

  • 9.1. Illumina Inc
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Strategic Initiatives
  • 9.2. Agilent Technologies
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Strategic Initiatives
  • 9.3. Roche Diagnostics
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Strategic Initiatives
  • 9.4. Cancer Genetics Inc
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Strategic Initiatives
  • 9.5. Bio-Rad Laboratories
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Strategic Initiatives
  • 9.6. Sigma Aldrich
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Strategic Initiatives
  • 9.7. Qiagen
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Strategic Initiatives
  • 9.8. Perkin Elmer
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Strategic Initiatives
  • 9.9. Affymetrix
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Strategic Initiatives
  • 9.10. BGI
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Strategic Initiatives
  • 9.11. Life technologies
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Strategic Initiatives
  • 9.12. GE Healthcare
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Strategic Initiatives
  • 9.13. Pacific Biosciences
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Strategic Initiatives
  • 9.14. Quest Diagnostics
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Strategic Initiatives
  • 9.15. Myriad Genetics
    • 9.15.1. Company Overview
    • 9.15.2. Financial Performance
    • 9.15.3. Product Benchmarking
    • 9.15.4. Strategic Initiatives
  • 9.16. Luminex
    • 9.16.1. Company Overview
    • 9.16.2. Financial Performance
    • 9.16.3. Product Benchmarking
    • 9.16.4. Strategic Initiatives
  • 9.17. Abbott Molecular
    • 9.17.1. Company Overview
    • 9.17.2. Financial Performance
    • 9.17.3. Product Benchmarking
    • 9.17.4. Strategic Initiatives
  • 9.18. Beckman Coulter, Inc
    • 9.18.1. Company Overview
    • 9.18.2. Financial Performance
    • 9.18.3. Product Benchmarking
    • 9.18.4. Strategic Initiatives
  • 9.19. Oxford Gene Technology Ltd.
    • 9.19.1. Company Overview
    • 9.19.2. Financial Performance
    • 9.19.3. Product Benchmarking
    • 9.19.4. Strategic Initiatives

List of Tables

  • TABLE 1: Genomics in cancer care market- Industry Snapshot & Key Buying Criteria, 2012 - 2022
  • TABLE 2: Global genomics in cancer care market, by product, 2012 - 2022 (USD Million)
  • TABLE 3: Global genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 4: Global genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 5: Global genomics in cancer care market, by end-use, 2012 - 2022(USD Million)
  • TABLE 6: Global Genomics in cancer care market, by region, 2012 - 2022 (USD Million)
  • TABLE 7: Genomics in cancer care- Key market driver analysis
  • TABLE 8: Genomics in cancer care market - Key market restraint analysis
  • TABLE 9: North America genomics in cancer care market, by product , 2012 - 2022 (USD Million)
  • TABLE 10: North America genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 11: North America genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 12: North America genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)
  • TABLE 13: U.S. genomics in cancer care market, by product, 2012 - 2022 (USD Million)
  • TABLE 14: U.S. genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 15: U.S. genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 16: U.S. genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)
  • TABLE 17: Canada genomics in cancer care market, by product , 2012 - 2022 (USD Million)
  • TABLE 18: Canada genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 19: Canada genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 20: Canada genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)
  • TABLE 21: Europe genomics in cancer care market, by product, 2012 - 2022 (USD Million)
  • TABLE 22: Europe genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 23: Europe genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 24: Europe genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)
  • TABLE 25: UK genomics in cancer care market, by product , 2012 - 2022 (USD Million)
  • TABLE 26: UK genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 27: UK genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 28: UK genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)
  • TABLE 29: Germany genomics in cancer care market, by product , 2012 - 2022 (USD Million)
  • TABLE 30: Germany genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 31: Germany genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 32: Germany genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)
  • TABLE 33: Asia Pacific genomics in cancer care market, by product , 2012 - 2022 (USD Million)
  • TABLE 34: Asia Pacific genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 35: Asia Pacific genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 36: Asia Pacific genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)
  • TABLE 37: Japan genomics in cancer care market, by product, 2012 - 2022 (USD Million)
  • TABLE 38: Japan genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 39: Japan genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 40: Japan genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)
  • TABLE 41: China genomics in cancer care market, by product , 2012 - 2022 (USD Million)
  • TABLE 42: China genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 43: China genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 44: China genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)
  • TABLE 45: India genomics in cancer care market, by product , 2012 - 2022 (USD Million)
  • TABLE 46: India genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 47: India genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 48: India genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)
  • TABLE 49: Latin America genomics in cancer care market, by product, 2012 - 2022 (USD Million)
  • TABLE 50: Latin America genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 51: Latin America genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 52: Latin America genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)
  • TABLE 53: Mexico genomics in cancer care market, by product , 2012 - 2022 (USD Million)
  • TABLE 54: Mexico genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 55: Mexico genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 56: Mexico genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)
  • TABLE 57: Brazil genomics in cancer care market, by product , 2012 - 2022 (USD Million)
  • TABLE 58: Brazil genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 59: Brazil genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 60: Brazil genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)
  • TABLE 61: MEA genomics in cancer care market, by product, 2012 - 2022 (USD Million)
  • TABLE 62: MEA genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 63: MEA genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 64: MEA genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)
  • TABLE 65: South Africa genomics in cancer care market, by product , 2012 - 2022 (USD Million)
  • TABLE 66: South Africa genomics in cancer care market, by application, 2012 - 2022 (USD Million)
  • TABLE 67: South Africa genomics in cancer care market, by technology, 2012 - 2022 (USD Million)
  • TABLE 68: South Africa genomics in cancer care market, by end-use, 2012 - 2022 (USD Million)

List of Figures

  • FIG. 1: Genomics in canecr care: Market segmentation
  • FIG. 2: Genomics in cancer care market, 2014 - 2022 (USD Million)
  • FIG. 3: Genomics in cancer care: Market dynamics
  • FIG. 4: Key opportunities prioritized
  • FIG. 5: Genomics in cancer care market Porter's analysis
  • FIG. 6: Genomics in cancer care market PESTEL analysis
  • FIG. 7: Genomics in cancer care technology development analysis, 2014 & 2022
  • FIG. 8: Genomics in cancer care revenue share by product, 2014 & 2022
  • FIG. 9: Instruments market, 2012 - 2022 (USD Million)
  • FIG. 10: Consumables market, 2012 - 2022 (USD Million)
  • FIG. 11: Services market, 2012 - 2022 (USD Million)
  • FIG. 12: Genomics in cancer caremarket share by application, 2014 & 2022
  • FIG. 13: Diagnostics market, 2012 - 2022 (USD Million)
  • FIG. 14: Personalized medicine market, 2012 - 2022 (USD Million)
  • FIG. 15: Drug discovery & development market, 2012 - 2022 (USD Million)
  • FIG. 16: Research market, 2012 - 2022 (USD Million)
  • FIG. 17: Genomics in cancer caremarket share by technology, 2014 & 2022
  • FIG. 18: Genome sequencing market, 2012 - 2022 (USD Million)
  • FIG. 19: PCR market, 2012 - 2022 (USD Million)
  • FIG. 20: Microarrays market, 2012 - 2022 (USD Million)
  • FIG. 21: Nuclic acid extraction & purification market, 2012 - 2022 (USD Million)
  • FIG. 22: Other market, 2012 - 2022 (USD Million)
  • FIG. 23: Genomics in cancer care revenue share by end-use, 2014 & 2022
  • FIG. 24: Hospitals market, 2012 - 2022 (USD Million)
  • FIG. 25: Research institutes market, 2012 - 2022 (USD Million)
  • FIG. 26: Academic institutes market, 2012 - 2022 (USD Million)
  • FIG. 27: Other market, 2012 - 2022 (USD Million)
  • FIG. 28: North America genomics in cancer care market, 2014 - 2022 (USD Million)
  • FIG. 29: U.S. genomics in cancer care market, 2014 - 2022 (USD Million)
  • FIG. 30: Canada genomics in cancer care market, 2014 - 2022 (USD Million)
  • FIG. 31: Europe genomics in cancer care market, 2014 - 2022 (USD Million)
  • FIG. 32: UK genomics in cancer care market, 2014 - 2022 (USD Million)
  • FIG. 33: Germany genomics in cancer care market, 2014 - 2022 (USD Million)
  • FIG. 34: Asia Pacific genomics in cancer care market, 2012 - 2022 (USD Million)
  • FIG. 35: Japan genomics in cancer care market, 2012 - 2022 (USD Million)
  • FIG. 36: China genomics in cancer care market, 2012 - 2022 (USD Million)
  • FIG. 37: India genomics in cancer care market, 2012 - 2022 (USD Million)
  • FIG. 38: Latin America genomics in cancer care market, 2012 - 2022 (USD Million)
  • FIG. 39: Mexico genomics in cancer care market, 2012 - 2022 (USD Million)
  • FIG. 40: Brazil genomics in cancer care market, 2012 - 2022 (USD Million)
  • FIG. 41: MEA genomics in cancer care market, 2012 - 2022 (USD Million)
  • FIG. 42: South Africa genomics in cancer care market, 2012 - 2022 (USD Million)
Back to Top